Probiotics in Intestinal Bacterial Overgrowth

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the present study is to demonstrate the effect of a mixture of four species of probiotics (Saccharomyces boulardii, Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5 and Lactobacillus plantarum) in patients with symptomatic irritable bowel syndrome (IBS) who have culture verified syndrome of intestinal bacterial overgrowth (SIBO) and those who do not have. This will provide direct evidence for the role of probiotics in treating part of the pathogenesis of IBS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome

NCT05064930

Irritable Bowel Syndrome

COMPLETED NA

A Novel Probiotic Mixture in Adults With IBS

NCT06610149

Irritable Bowel Syndrome

COMPLETED NA

Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating

NCT00618904

Pain

COMPLETED NA

Effect of a Probiotic Formula on Reducing SIBO in IBS Patients

NCT04316806

Irritable Bowel Syndrome Small Intestinal Bacterial Overgrowth

TERMINATED NA

Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome

NCT05819281

Irritable Bowel Syndrome

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder. Pathogenesis remains multifactorial. Better understanding of the interaction of the host with intestinal microbiota the last decade led to the knowledge that many of the symptoms of IBS, mainly bloating and diarrhea, are related with the overgrowth of bacteria of colonic type in the small intestine. This overgrowth frames the syndrome of intestinal bacterial overgrowth (SIBO) where colonic type of bacteria predominate in the proximal parts of the small intestine. Fermentation of dietary carbohydrates by the bacteria colonizers of SIBO ends with the over-production of gas generating thus symptoms of IBS. The relationship between IBS and SIBO was found by a series of prospective observational studies using the lactulose and the glucose tolerance tests for the diagnosis of SIBO. Using this test, the prevalence of SIBO in patients with IBS ranged between 65 and 85%. The gold-standard technique for the diagnosis of SIBO is the quantitative culture of the content of the proximal intestine i.e. of the duodenum after upper GI tract endoscopy. Few studies are available with this design and they suggest a growth of colonic type of flora at counts equal to or greater than 10\^5 cfu/ml as diagnostic of SIBO. Based on systematic review of the literature but also on data generated in a cohort of 320 consecutive patients undergoing upper GI tract endoscopy, normal subjects are never greater than 10\^3 cfu/m in the duodenum. In the latter publication coming from Athens, using variable cut-offs greater than 10\^3 or 10\^4 or 10\^5 cfu/ml for the diagnosis of SIBO, the frequency of SIBO was significantly greater among sufferers than among non-sufferers from IBS.

Oral supplementation with probiotics may be a rational approach for the eradication of SIBO and subsequently of the symptoms of IBS. The majority of probiotic bacteria belong to the Lactobacillus and Bifidobacterium genera. They are Gram-positive lactic acid-producing bacteria that constitute a major part of the normal intestinal microflora in animals and humans. The rationale behind their use as a therapeutic strategy in IBS is that orally administered probiotics may replace the overgrown enteric-type bacteria of SIBO. Four randomized clinical trials are available evaluating the efficacy of orally administered probiotics in IBS. The common findings of these trials are that a) efficacy refers to the improvement of symptoms of bloating and of diarrhea that are typical symptoms of the presence of SIBO; and b) efficacy is usually found when mixtures of different species of probiotics are used. However, no study has ever tested the efficacy of probiotics in patients with IBS and SIBO proven by small intestinal culture.

The aim of the present study is to demonstrate the effect of a mixture of four species of probiotics (Saccharomyces boulardii, Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5 and Lactobacillus plantarum) in patients with symptomatic IBS who have culture verified SIBO and those who do not have. This will provide direct evidence for the role of probiotics in treating part of the pathogenesis of IBS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotics in SIBO

Administration of probiotics in patients with IBS and SIBO

Group Type EXPERIMENTAL

Probiotics in SIBO

Intervention Type DIETARY_SUPPLEMENT

Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days

Probiotics

Administration of probiotics in patients with IBS without SIBO

Group Type ACTIVE_COMPARATOR

Probiotics

Intervention Type DIETARY_SUPPLEMENT

One capsule twice daily for 30 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotics in SIBO

Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days

Intervention Type DIETARY_SUPPLEMENT

Probiotics

One capsule twice daily for 30 days

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Saccharomyces Bifidobacterium Lactobacillus species

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years
2. Both genders
3. Written informed consent by study participants
4. Presence of IBS according to Rome III criteria
5. Equal number of SIBO-positive and SIBO-negative patients

Exclusion Criteria

1. Age \<18 years
2. Deny to consent
3. Pregnancy or lactation
4. Presence of inflammatory bowel disease
5. Presence of acute GI tract infection
6. Diabetes mellitus type 1 or type 2
7. Use of laxatives and antibiotics within the preceding 6 weeks
8. Presence of fever, abdominal mass, signs of bowel obstruction and/or leucocytosis
9. Abnormal serum levels of thyroid -stimulating hormone.
10. History of colon cancer or diverticulitis
11. Infection by human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus
12. Patients with celiac disease defined by biopsy of the duodenal mucosa.
13. History of scleroderma and gastroparesis
14. Pregnancy or planning pregnancy the next 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No